Ensysce Biosciences
LA JOLLA, California, United States · Banking, Biotechnology, Finance
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Key facts
- Headquarters
- LA JOLLA, California, United States
- Employees
- 12
- Industries
- Banking, Biotechnology, Finance
- Status
- Public (ENSC)
- Website
- ensysce.com
- Company page
Recent activity at Ensysce Biosciences
- : SEC 8-K (8.01): On August 25, 2026, Ensysce Biosciences Inc. received notification from Nasdaq confirming that the company complies with the $2.5 million stockholders’ equity requirement under Rule 5550(b)(1). This followed a previous notice on May 21, 2026, regarding potential delisting due to non-compliance as of March 31, 2026. The company submitted a compliance plan within the required timeframe and believes it can demonstrate continued compliance in its next periodic report. Failure to do so will lead to a delisting from Nasdaq, impacting its ability to raise capital and trade publicly.
- : Ensysce Biosciences
- : Ensysce acquires Cy Biopharma for $77 million
- : Guanajuato Silver acquires Bolanitos for growth
- : Cyberhaven launches Agentic AI Security to enhance AI governance and security for enterprises.
- : Dynamo Capital
- : Cognota, a Toronto-based learning operations software provider, raised $5.75 million in Series B funding led by Blossom Street Ventures to accelerate the development of AI agents.
- : SEC 8-K (1.01): On November 13, 2025, Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement with an institutional investor to conduct a registered direct offering. The agreement involves the issuance of 1,513 shares of Series B Preferred Stock and up to 665,922 shares of Common Stock, potentially generating gross proceeds of approximately $1.7 million before fees and expenses. The closing of this transaction took place on November 14, 2025, indicating a strategic move to bolster the company's capital structure. This agreement could significantly impact the company's funding capabilities moving forward.
- : Ensysce Biosciences
- : Ensysce Biosciences
Ensysce Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $77.2M |
| Mar 2026 | Venture | $59.2M |
| Mar 2026 | Series B | $5.8M |
| Apr 2025 | Seed | $2.2M |
| Apr 2025 | Seed | $1.1M |
Leadership
- D Kirkpatrick, Executive Officer, Director
- Bob Gower, Director
- William Chang, Director
- Andrew Benton, Director
- Steve Martin, Director
- Adam Levin, Director
- Curtis Rosebraugh, Director
- Steve Klein, Director
- Paul Davis, Consultant, Fintechs
- Andrew Simon, Owner
- Marty Arrivo, Executive Director
- Aracibo Quintana, Director
Verified email and direct lines for Ensysce Biosciences’s decision-makers are on Fundz. See plans
Employee benefit plans
Ensysce Biosciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Ensysce Biosciences in the news
- Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Yahoo Finance (Sep 14, 2026)
- A study plan for a pain condition with no treatment that cures it reaches UK regulators. - stocktitan.net (Sep 24, 2026)
- Ensysce Biosciences Awarded $5.3 Million To Advance Overdose-Protected Opioid - Pulse 2.0 (Jul 15, 2026)
- Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance (Aug 13, 2026)
- More than 320 pain professionals attended Ensysce’s symposium on complex pain. - stocktitan.net (Sep 15, 2026)
- Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - Yahoo Finance (Aug 06, 2026)
- Federal funds back Ensysce opioid technology designed to limit overdose - stocktitan.net (Jul 14, 2026)
- Why is Ensysce Biosciences stock surging today? - Investing.com (Aug 04, 2026)
Companies similar to Ensysce Biosciences
- Nexi S.p.A · Banking, Biotechnology, Finance, Financial Services, Fintech, Lending, Manufacturing
- Eyenovia · Finance, Financial Services, Fintech, Healthcare, Lending, Manufacturing
- Charter Communications · Banking, Biotechnology, Finance, Financial Services, Hardware, Lending
- Alkami Technology · Banking, Finance, Financial Services, Fintech, Hardware, Lending
- Andersen Corporation · Banking, Finance, Financial Services, Fintech, Lending, Manufacturing
About Ensysce Biosciences: questions and answers
What does Ensysce Biosciences do?
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Where is Ensysce Biosciences headquartered?
Ensysce Biosciences is headquartered in LA JOLLA, California, United States.
How many employees does Ensysce Biosciences have?
Ensysce Biosciences has about 12 employees.
Has Ensysce Biosciences raised funding?
Yes. Fundz has recorded 5 funding events for Ensysce Biosciences. The most recent, $77.2M, was in Aug 2026.
What is the latest news on Ensysce Biosciences?
On Aug 25, 2026, SEC 8-K (8.01): On August 25, 2026, Ensysce Biosciences Inc. received notification from Nasdaq confirming that the company complies with the $2.5 million stockholders’ equity requirement under Rule 5550(b)(1). This followed a previous notice on May 21, 2026, regarding potential delisting due to non-
Is Ensysce Biosciences a public company?
Yes. Ensysce Biosciences is publicly traded under the ticker ENSC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy